Literature DB >> 16474381

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.

Thijn R Brummelkamp1, Armida W M Fabius, Jasper Mullenders, Mandy Madiredjo, Arno Velds, Ron M Kerkhoven, René Bernards, Roderick L Beijersbergen.   

Abstract

The identification of the cellular targets of small molecules with anticancer activity is crucial to their further development as drug candidates. Here, we present the application of a large-scale RNA interference-based short hairpin RNA (shRNA) barcode screen to gain insight in the mechanism of action of nutlin-3 (1). Nutlin-3 is a small-molecule inhibitor of MDM2, which can activate the p53 pathway. Nutlin-3 shows strong antitumor effects in mice, with surprisingly few side effects on normal tissues. Aside from p53, we here identify 53BP1 as a critical mediator of nutlin-3-induced cytotoxicity. 53BP1 is part of a signaling network induced by DNA damage that is frequently activated in cancer but not in healthy tissues. Our results suggest that nutlin-3's tumor specificity may result from its ability to turn a cancer cell-specific property (activated DNA damage signaling) into a weakness that can be exploited therapeutically.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474381     DOI: 10.1038/nchembio774

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   15.040


  72 in total

1.  An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.

Authors:  Casey W Shuptrine; Reham Ajina; Elana J Fertig; Sandra A Jablonski; H Kim Lyerly; Zachary C Hartman; Louis M Weiner
Journal:  Cancer Immunol Immunother       Date:  2017-08-02       Impact factor: 6.968

Review 2.  Functional genomics to uncover drug mechanism of action.

Authors:  Sebastian M B Nijman
Journal:  Nat Chem Biol       Date:  2015-11-17       Impact factor: 15.040

Review 3.  A primer on using pooled shRNA libraries for functional genomic screens.

Authors:  Guang Hu; Ji Luo
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2012-02       Impact factor: 3.848

4.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

5.  RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

Authors:  Jeffrey W Tyner; Denise K Walters; Stephanie G Willis; Mary Luttropp; Jason Oost; Marc Loriaux; Heidi Erickson; Amie S Corbin; Thomas O'Hare; Michael C Heinrich; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

Review 6.  High-throughput analysis of signals regulating stem cell fate and function.

Authors:  Gregory H Underhill; Sangeeta N Bhatia
Journal:  Curr Opin Chem Biol       Date:  2007-07-25       Impact factor: 8.822

7.  MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival.

Authors:  Eleonora Forte; Micah A Luftig
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

8.  The RNF8/RNF168 ubiquitin ligase cascade facilitates class switch recombination.

Authors:  Shaliny Ramachandran; Richard Chahwan; Rajeev M Nepal; Darina Frieder; Stephanie Panier; Sergio Roa; Ahmad Zaheen; Daniel Durocher; Matthew D Scharff; Alberto Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling.

Authors:  Ioulia Kachirskaia; Xiaobing Shi; Hiroshi Yamaguchi; Kan Tanoue; Hong Wen; Evelyn W Wang; Ettore Appella; Or Gozani
Journal:  J Biol Chem       Date:  2008-10-07       Impact factor: 5.157

Review 10.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.